knowledge -WSS

knowledge

author：fashion 2025-10-08 15:27:59 - browse：75

Today, if you want to know what scary family health secrets lay buried in your DNA or get screened for a lurking cancer, you have a lot of options. Laboratories have developed more than 75,000 genetic tests, with about 10 new ones entering the market daily. By the end of 2019, more than 26 million Americans had had their DNA decoded to some degree or another. Since then, that number has surely grown.

But this testing frenzy would have been inconceivable just 10 years ago. In part, that’s because the technology back then was so expensive. More importantly, until 2013, it was common practice for gene-hunting academics and companies to lock up their discoveries with DNA patents, effectively carving up the human genome into mini-monopolies. That year, the U.S. Supreme Court threw a bomb into the biotech world when it took up a landmark case that pitted cancer survivors and the American Civil Liberties Union against a diagnostics company called Myriad Genetics, which had obtained exclusive patents on the cancer-causing BRCA genes and made billions of dollars selling tests for them.

A new book called “The Genome Defense,” written by University of Utah science and technology law expert Jorge Contreras and being published Oct. 26, provides a front-row seat to the courtroom drama that would upend three decades of federal intellectual property law and chart a new course toward balancing corporate profits with the rights of all people to the information written into their DNA.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Cancer drug shortages' outsize impact on ovarian cancer patients

knowledge

WSS

New definition of a human embryo proposed amid rapid advances

Congress must give Medicare recipients genetic counseling access

How CO2 helps viruses stay alive longer in the air

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

Clinical trials must include more disabled people

Clinical trials must include more disabled people

entertainment

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

ProMED sees offers of support, but its future remains unclear

New air purifier tech could be key to improving indoor air quality

Baltimore teen accused of firing into crowd during block party mass shooting

Bright Health sells Medicare Advantage business to Molina

STAT wants to know your pick for a great summer read or listen

In age of alternative facts, a scholarly course on calling out crap

Living with Hashimoto's and celiac disease, and med school, too

In age of alternative facts, a scholarly course on calling out crap

Baltimore teen accused of firing into crowd during block party mass shooting

focus

UnitedHealth CEO's Medicaid comments send insurer stocks diving

Congress must give Medicare recipients genetic counseling access

Fight over Supreme Court dialysis ruling puts kidney patients at risk

ProMED sees offers of support, but its future remains unclear

FTC loses bid to block Novant's North Carolina hospital merger

Congress needs to close a vaccine

entertainment

hotspot

knowledge

focus